ReviewThe lancet. Gastroenterology & hepatology2021
The relationship between gastrointestinal cancers and the microbiota.
Review in The lancet. Gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of Clear Aligners on the Oral Microbiome: A Systematic Review of Current Evidence.Clinical and experimental dental research · 2026Pooled it
- Gut microbiota and gastrointestinal tumors: insights from a bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Side-effects of hyperthermic intraperitoneal chemotherapy in patients with gastrointestinal cancers.PeerJ · 2023Pooled it
- Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.Gut microbes · 2026Review
- The role of gut microbiome in aging-associated diseases: where do we stand now and how technology will transform the future.Gut microbes · 2026Review
- Human salivary microbiome as a potential non-invasive biomarker for early-onset colorectal cancer screening: a prospective study.BMC microbiology · 2026Article
- Article
- Dose-Response Relationship of Niclosamide and Metformin Combination in ApcGut and liver · 2026Article
- Microbiota-Derived Proteins Shape T Cell Responses in Healthy and Colorectal Cancer Subjects.Biomedicines · 2026Article
- SMTdb: A Comprehensive Spatial Meta-Transcriptome Resource in Cancer.Molecular biology and evolution · 2025Article
- The microbiota in radiotherapy-induced cancer immunosurveillance.Nature reviews. Clinical oncology · 2025Review
- Integrated spatial multi-omics profiling of Fusobacterium nucleatum in breast cancer unveils its role in tumour microenvironment modulation and cancer progression.Clinical and translational medicine · 2025Article
- Microbiome influence in gastric cancer progression and therapeutic strategies.Frontiers in medicine · 2025Review
- Gut Microbiota Interacts with Dietary Habits in Screenings for Early Detection of Colorectal Cancer.Nutrients · 2024Article
- Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma.Applied microbiology and biotechnology · 2024Article
- Identification and validation of microbial biomarkers from cross-cohort datasets using xMarkerFinder.Nature protocols · 2024Review
- The emerging tumor microbe microenvironment: From delineation to multidisciplinary approach-based interventions.Acta pharmaceutica Sinica. B · 2024Review
- Intratumoral microorganisms in tumors of the digestive system.Cell communication and signaling : CCS · 2024Review
- Inhibition of Cancer Development by Natural Plant Polyphenols: Molecular Mechanisms.International journal of molecular sciences · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The contribution of the microbiota to disease progression and treatment efficacy is often neglected when determining who is at the highest risk of developing gastrointestinal cancers or designing treatment strategies for patients. We reviewed the current literature on the effect of the human microbiota on cancer risk, prognosis, and treatment efficacy. We highlight emerging research that seeks to identify microbial signatures as biomarkers for various gastrointestinal cancers, and discuss how we could harness knowledge of the microbiome to detect, prevent, and treat these cancers. Finally, we outline further research needed in the field of gastrointestinal cancers and the microbiota, and describe the efforts required to increase the accuracy and reproducibility of data linking the microbiome to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.